Pan Optica

Title

A Phase 1, Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD)

The purpose of this study is to assess the safety and tolerability of the investigational eye drop solution, PAN-90806. The biological response to the eye drops will also be assessed to see if the drug helps slow the progression of neovascular age-related macular degeneration. Participants (age 50 years and older) enrolled in the study will be randomized into one of three study arms (1 mg/ml BID, 2 mg/ml BID, 4 mg/ml QD).